BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

392 related articles for article (PubMed ID: 27271357)

  • 1. Cost-effectiveness analysis of tenofovir disoproxil fumarate for treatment of chronic hepatitis B in China.
    Ke W; Zhang C; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
    Hepatol Int; 2016 Nov; 10(6):924-936. PubMed ID: 27271357
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness comparison of lamivudine plus adefovir combination treatment and nucleos(t)ide analog monotherapies in Chinese chronic hepatitis B patients.
    Zhang C; Ke W; Liu L; Gao Y; Yao Z; Ye X; Zhou S; Yang Y
    Drug Des Devel Ther; 2016; 10():897-910. PubMed ID: 27041994
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-utility analysis of tenofovir disoproxil fumarate in the treatment of chronic hepatitis B.
    Dakin H; Bentley A; Dusheiko G
    Value Health; 2010 Dec; 13(8):922-33. PubMed ID: 20825619
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-Effectiveness Comparison Between the Response-Guided Therapies and Monotherapies of Nucleos(t)ide Analogues for Chronic Hepatitis B Patients in China.
    Lai K; Zhang C; Ke W; Gao Y; Zhou S; Liu L; Yang Y
    Clin Drug Investig; 2017 Mar; 37(3):233-247. PubMed ID: 27928739
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness analysis of lamivudine, telbivudine, and entecavir in treatment of chronic hepatitis B with adefovir dipivoxil resistance.
    Wang G; Liu Y; Qiu P; Zhou SF; Xu L; Wen P; Wen J; Xiao X
    Drug Des Devel Ther; 2015; 9():2839-46. PubMed ID: 26082614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.
    Shepherd J; Jones J; Takeda A; Davidson P; Price A
    Health Technol Assess; 2006 Aug; 10(28):iii-iv, xi-xiv, 1-183. PubMed ID: 16904047
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis B from a Canadian public payer perspective.
    Dakin H; Sherman M; Fung S; Fidler C; Bentley A
    Pharmacoeconomics; 2011 Dec; 29(12):1075-91. PubMed ID: 22077579
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and cost-effectiveness of antiviral regimens for entecavir-resistant hepatitis B: A systematic review and network meta-analysis.
    Yang SS; Cai CW; Ma XQ; Xu J; Yu CB
    Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):507-514. PubMed ID: 33051132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness analysis of different rescue therapies in patients with lamivudine-resistant chronic hepatitis B in China.
    Wu B; Shen J; Cheng H
    BMC Health Serv Res; 2012 Nov; 12():385. PubMed ID: 23137013
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of Lamivudine, Telbivudine, Adefovir Dipivoxil and Entecavir on decompensated hepatitis B virus-related cirrhosis.
    Wang GL; Liu Y; Qiu P; Zhou SF; Xu LF; Wen P; Wen JB; Xiao XZ
    Eur Rev Med Pharmacol Sci; 2016 Mar; 20(5):866-72. PubMed ID: 27010143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial.
    Lim YS; Gwak GY; Choi J; Lee YS; Byun KS; Kim YJ; Yoo BC; Kwon SY; Lee HC
    J Hepatol; 2019 Jul; 71(1):35-44. PubMed ID: 30876946
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tenofovir-based rescue therapy for chronic hepatitis B patients who had failed treatment with lamivudine, adefovir, and entecavir.
    Kim BG; Jung SW; Kim EH; Kim JH; Park JH; Sung SJ; Park BR; Kim MH; Kim CJ; Lee BU; Park JH; Jeong ID; Bang SJ; Shin JW; Park NH
    J Gastroenterol Hepatol; 2015 Oct; 30(10):1514-21. PubMed ID: 25973716
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of long-term tenofovir-based rescue therapy in patients with chronic hepatitis B refractory to nucleoside/nucleotide analogs.
    Suzuki F; Suzuki Y; Hosaka T; Sezaki H; Akuta N; Fujiyama S; Kawamura Y; Kobayashi M; Saitoh S; Arase Y; Ikeda K; Kobayashi M; Mineta R; Suzuki Y; Kumada H
    J Gastroenterol; 2017 May; 52(5):641-651. PubMed ID: 27699721
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
    Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
    Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenofovir disoproxil fumarate for the treatment of chronic hepatitis B infection.
    Jones J; Colquitt J; Shepherd J; Harris P; Cooper K
    Health Technol Assess; 2010 May; 14 Suppl 1():23-9. PubMed ID: 20507800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of nucleoside analog therapy for hepatitis B in China: a Markov analysis.
    Wu B; Li T; Chen H; Shen J
    Value Health; 2010 Aug; 13(5):592-600. PubMed ID: 20561341
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Compare with safety and efficacy of entecavir and adefovir dipivoxil combination therapy and tenofovir disoproxil fumarate monotherapy for chronic hepatitis B patient with adefovir-resistant.
    Lai MC; Lian JS; Zhang WJ; Xu J; Zhou L; Zheng SS
    Math Biosci Eng; 2019 Oct; 17(1):627-635. PubMed ID: 31731368
    [No Abstract]   [Full Text] [Related]  

  • 18. A cost-utility analysis of drug treatments in patients with HBeAg-positive chronic hepatitis B in Thailand.
    Tantai N; Chaikledkaew U; Tanwandee T; Werayingyong P; Teerawattananon Y
    BMC Health Serv Res; 2014 Apr; 14():170. PubMed ID: 24731689
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Entecavir plus tenofovir combination therapy for chronic hepatitis B in patients with previous nucleos(t)ide treatment failure.
    Zoulim F; Białkowska-Warzecha J; Diculescu MM; Goldis AE; Heyne R; Mach T; Marcellin P; Petersen J; Simon K; Bendahmane S; Klauck I; Wasiak W; Janssen HL
    Hepatol Int; 2016 Sep; 10(5):779-88. PubMed ID: 27206517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Economic Evaluation of Oral Nucleos(t)ide Analogues for Patients with Chronic Hepatitis B in Thailand.
    Dilokthornsakul P; Sawangjit R; Tangkijvanich P; Chayanupatkul M; Tanwandee T; Sukeepaisarnjaroen W; Sriuttha P; Permsuwan U
    Appl Health Econ Health Policy; 2022 Jul; 20(4):587-596. PubMed ID: 35141850
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.